Evidence Hub

Low-dose tadalafil improves arterial erectile dysfunction

Xu ZP, Chen Y, Sun C, Dai YT

Zhonghua nan ke xue = National journal of andrology, 2009

Abstract

OBJECTIVE: To evaluate the effect of low-dose phosphodiesterase type 5 inhibitor tadalafil on arterial erectile dysfunction.

METHODS: Forty-three patients with arterial erectile dysfunction were requested to take 5 mg tadalafil after supper on alternate days for 4 weeks. All the patients were scored on IIEF-5 and received intracavernous injection of 10 microg prostaglandin E1, followed by measurement of the peak systolic velocity (PSV) of the cavernosal artery by color Doppler ultrasonography.

RESULTS: Statistic analyses showed an obvious increase in the IIEF-5 score and PSV after the treatment, with significant differences from the baseline (P < 0.01).

CONCLUSION: Low-dose tadalafil can significantly improve the PSV of the cavernosal artery and hence the erectile function of arterial ED patients.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free